The role of glucose as an independent cardiovascular risk factor

Current Diabetes Reports

Volumn 7, Issue 1, 2007, Pages 43-49

  Middelbeek, R Jan Willem ^a   Horton, Edward S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; VON WILLEBRAND FACTOR;

BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HEART INFARCTION; HEMOGLOBIN DETERMINATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC HEART DISEASE; MORBIDITY; MORTALITY; ONSET AGE; ORAL GLUCOSE TOLERANCE TEST; PATHOPHYSIOLOGY; POSTPRANDIAL STATE; PROGNOSIS; REVIEW; RISK FACTOR; RISK REDUCTION; SMOKING; SURVIVAL RATE; SURVIVAL TIME;

CARDIOVASCULAR DISEASES; DISEASE SUSCEPTIBILITY; FASTING; GLUCOSE; HEMOGLOBIN A; HUMANS; POSTPRANDIAL PERIOD;

EID: 33847409390     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-007-0008-4     Document Type: Review

References (39)

1. Kannel WB, McGee DL: Diabetes and cardiovascular disease. The Framingham study. JAMA 1979, 241:2035-2038.
2. Laakso M: Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 1999, 48:937-942.
3. Koskinen P, Manttari M, Manninen V, et al.: Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992, 15:820-825.
4. Bierman EL: George Lyman Duff Memorial Lecture. Atherogenesis in diabetes Arterioscler Thromb 1992, 12:647-656.
5. Stratton IM, Adler AI, Neil HA, et al.: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000, 321:405-412.
6. Klein R: Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 1995, 18:258-268.
7. Niskanen L, Turpeinen A, Penttila I, Uusitupa MI: Hyperglycemia and compositional lipoprotein abnormalities as predictors of cardiovascular mortality in type 2 diabetes: a 15-year follow-up from the time of diagnosis. Diabetes Care 1998, 21:1861-1869.
8. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group [no authors listed] Lancet 1998, 352:837-853.
9. Jesudason DR, Dunstan K, Leong D, Wittert GA: Macrovascular risk and diagnostic criteria for type 2 diabetes: implications for the use of FPG and HbA(1c) for cost-effective screening. Diabetes Care 2003, 26:485-490.
10. Temelkova-Kurktschiev TS, Koehler C, Henkel E, et al.: Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. Diabetes Care 2000, 23:1830-1834.
11. Lehto S, Ronnemaa T, Haffner SM, et al.: Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes 1997, 46:1354-1359.
12. Heine RJ, Balkan B, Ceriello A, et al.: What does postprandial hyperglycaemia mean? Diabet Med 2004, 21:208-213.
13. Balkau B, Shipley M, Jarrett RJ, et al.: High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 1998, 21:360-367.
14. Fuller JH, Shipley MJ, Rose G, et al.: Mortality from coronary heart disease and stroke in relation to degree of glycaemia: the Whitehall study. Br Med J (Clin Res Ed) 1983, 287:867-870.
15. Kannel WB, McGee D, Gordon T: A general cardiovascular risk profile: the Framingham Study. Am K Cardiol 1976, 38:46-51.
16. Eschwege E, Richard JL, Thibult N, et al.: Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels. The Paris Prospective Study, ten years later. Horm Metab Res Suppl 1985, 15:41-46.
17. Pyorala K: Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care 1979, 2:131-141.
18. Park S, Barrett-Connor E, Wingard DL, et al.: GHb is a better predictor of cardiovascular disease than fasting or postchallenge plasma glucose in women without diabetes. The Rancho Bernardo Study. Diabetes Care 1996, 19:450-456.
19. Burchfiel CM, Curb JD, Rodriguez BL, et al.: Glucose intolerance and 22-year stroke incidence. The Honolulu Heart Program. Stroke 1994, 25:951-957.
20. Selvin E, Marinopoulos S, Berkenblit G, et al.: Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004, 141:421-431.
21. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group [no authors listed]. N Engl J Med 1993, 329:977-986.
22. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. The Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group [no authors listed]. N Engl J Med 2005, 353:2643-2653.
23. Shichiri M, Kishikawa H, Ohkubo Y, Wake N: Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000, 23(suppl 2): B21-B29.
24. Kuusisto J, Mykkanen L, Pyorala K, Laakso M: NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 1994, 43:960-967.
25. Standl E, Balletshofer B, Dahl B, et al.: Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: the Munich General Practitioner Project. Diabetologia 1996, 39:1540-1545.
26. Bjornholt JV, Erikssen G, Aaser E, et al.: Fasting blood glucose: an underestimated risk factor for cardiovascular death. Results from a 22-year follow-up of healthy nondiabetic men. Diabetes Care 1999, 22:45-49.
27. Tominaga M, Eguchi H, Manaka H, et al.: Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999, 22:920-924.
28. Fujishima M, Kiyohara Y, Kato I, et al.: Diabetes and cardiovascular disease in a prospective population survey in Japan: the Hisayama Study. Diabetes 1996, 45(suppl 3):S14-S16.
29. Henry P, Thomas F, Benetos A, Guize L: Impaired fasting glucose, blood pressure and cardiovascular disease mortality. Hypertension 2002, 40:458-463.
30. Simons LA, Friedlander Y, McCallum J, Simons J: Fasting plasma glucose in non-diabetic elderly women predicts increased all-causes mortality and coronary heart disease risk. Aust N Z J Med 2000, 30:41-47.
31. Tanne D, Koren-Morag N, Goldbourt U: Fasting plasma glucose and risk of incident ischemic stroke or transient ischemic attacks: a prospective cohort study. Stroke 2004, 35:2351-2355.
32. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe [no authors listed]. Lancet 1999, 354:617-621.
33. Balkan B, Forhan A, Eschwege E: Two-hour plasma glucose is not unequivocally predictive for early death in men with impaired fasting glucose: more results from the Paris Prospective Study. Diabetologia 2002, 45:1224-1230.
34. Donahue RP, Abbott RD, Reed DM, Yano K: Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry. Honolulu Heart Program. Diabetes 1987, 36:689-692.
35. Qiao Q, Tuomilehto J, Borch-Johnsen K: Post-challenge hyperglycaemia is associated with premature death and macrovascular complications. Diabetologia 2003, 46(suppl 1):M17-M21.
36. Hanefeld M, Fischer S, Julius U, et al.: Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996, 39:1577-1583.
37. de Vegt F, Dekker JM, Ruhe HG, et al.: Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia 1999, 42:926-931.
38. 1c. J Clin Epidemiol 2004, 57:590-596.
39. Cavalot F, Petrelli A, Traversa M, et al.: Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women, lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab 2006, 91:813-819.